Going Up: What’s Behind the Growth in IVIG Demand
The U.S. market for IVIG continues to grow well over 5 percent annually. What is driving the market demand?
Blood Protein Therapeutics: It All Starts with the Plasma
The plasma donor is the first vital part of the process to produce safe and effective plasma protein therapeutics, and the industry prioritizes the safety and health of its plasma donors.
Single IVIG Infusion Associated with Improved Recovery and Histopathological Profile in Rat Model of Ischemic Stroke
Turkish investigators conducted an exploratory study of IVIG usage in the experimentally induced middle cerebral artery occlusion rat stroke model.
Biomarker Found in CIDP Patients Who Don’t Respond to IVIG Therapy
A recent study discovered a biomarker in chronic inflammatory demyelinating polyneuropathy patients that explains why they don’t respond to intravenous immune globulin therapy.
BabyBIG: Definitive Early Immunotherapy for Infant Botulism
Explore the history and trace the development of BabyBIG, the life-saving immunotherapy for infant botulism.
FDA Approves NUWIQ to Treat Hemophilia A
The U.S. Food and Drug Administration ha approved Octapharma’s NUWIQ, antihemophilic factor (recombinant), an intravenous therapy for adults and children living with hemophilia A.
Autoimmune Disease: A More Effective Treatment on the Horizon?
IVIG has enhanced and even saved the lives of many autoimmune disease patients. But, the cost of therapy, large dose size and limited raw materials are serious limitations to an otherwise efficacious, well-tolerated therapy.
Gammaplex Approved for PI Patients 2 Years and Older
The U.S. Food and DrugAdministration (FDA) approved BioProducts Laboratory’s Gammaplex(immune globulin intravenous [human]5% liquid) for pediatric patients 2 years of age and older who have primary immunodeficiency disease (PI).
Recombinant IVIG Granted Orphan Drug Designation for CIDP
Pfizer (a licensee of Gliknik Inc.) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its recombinant intravenous immune globulin (IVIG)-mimetic drug
GL-2045 to treat chronic inflammatory demyelinating polyneuropathy (CIDP).
ADMA Biologics’ IVIG Product (RI-002) Receives Positive Phase III Results
ADMA Biologics has received positive results on the primary and secondary endpoint evaluations from the Phase III trial for its intravenous immune globulin (IVIG) product RI-002 to treat primary immunodeficiency disease(PI).